表紙
市場調查報告書

肺移植排斥反應:開發中產品分析

Lung Transplant Rejection - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 395245
出版日期 內容資訊 英文 80 Pages
訂單完成後即時交付
價格
Back to Top
肺移植排斥反應:開發中產品分析 Lung Transplant Rejection - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 80 Pages
簡介

肺移植是各種肺部疾病的治療方法。肺移植是以健康的肺臟取代受傷或患病的肺。與移植有關的危險因素有出血,感染,血栓和心血管疾病。移植後,免疫系統可能會視移植的新肺為外來異物加以攻擊。因此患者可能會發生併發症,最後排斥新器官。可同時施用免疫抑製藥物,根據各種免疫反應來防止身體識別或攻擊外來器官,以阻止器官排斥並促進移植成功。

本報告提供肺移植排斥反應相關的藥物的開發情形調查分析,提供開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

肺移植排斥反應概要

治療藥的開發

  • 開發中產品概要
  • 各企業的開發平台
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Dompe Farmaceutici SpA
  • Kamada Ltd
  • Novartis AG
  • Quark Pharmaceuticals Inc

藥物簡介

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11760IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Lung Transplant Rejection - Pipeline Review, H2 2019, provides an overview of the Lung Transplant Rejection (Immunology) pipeline landscape.

Lung transplantation is the therapy used in various lung diseases. Lung transplant replaces an injured or diseased lung with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted lung as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Lung Transplant Rejection - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Lung Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Lung Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Lung Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 9 respectively.

Lung Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Lung Transplant Rejection (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Lung Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Lung Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Lung Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Lung Transplant Rejection (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Lung Transplant Rejection (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Lung Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Lung Transplant Rejection - Overview
    • Lung Transplant Rejection - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Lung Transplant Rejection - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Lung Transplant Rejection - Companies Involved in Therapeutics Development
    • Amgen Inc
    • Astellas Pharma Inc
    • Exscien Corp
    • F4 Pharma GmbH
    • Kamada Ltd
    • MimeTech Srl
    • Proteo Inc
    • Quark Pharmaceuticals Inc
    • Radikal Therapeutics Inc
    • Sangamo Therapeutics Inc
    • Theravance Biopharma Inc
  • Lung Transplant Rejection - Drug Profiles
  • Lung Transplant Rejection - Dormant Projects
  • Lung Transplant Rejection - Discontinued Products
  • Lung Transplant Rejection - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Lung Transplant Rejection, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Lung Transplant Rejection - Pipeline by Amgen Inc, H2 2019
  • Lung Transplant Rejection - Pipeline by Astellas Pharma Inc, H2 2019
  • Lung Transplant Rejection - Pipeline by Exscien Corp, H2 2019
  • Lung Transplant Rejection - Pipeline by F4 Pharma GmbH, H2 2019
  • Lung Transplant Rejection - Pipeline by Kamada Ltd, H2 2019
  • Lung Transplant Rejection - Pipeline by MimeTech Srl, H2 2019
  • Lung Transplant Rejection - Pipeline by Proteo Inc, H2 2019
  • Lung Transplant Rejection - Pipeline by Quark Pharmaceuticals Inc, H2 2019
  • Lung Transplant Rejection - Pipeline by Radikal Therapeutics Inc, H2 2019
  • Lung Transplant Rejection - Pipeline by Sangamo Therapeutics Inc, H2 2019
  • Lung Transplant Rejection - Pipeline by Theravance Biopharma Inc, H2 2019
  • Lung Transplant Rejection - Dormant Projects, H2 2019

List of Figures

  • Number of Products under Development for Lung Transplant Rejection, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top